Bioresorbable cardiovascular stents are gaining momentum and drawing more investor interest. This time, the spotlight falls on Amaranth Medical, which is well underway with plans to raise a $25 million Series B funding round.
South Korean scientists believe they may have solved what causes very late stent thrombosis (blood clots) after drug-eluting or bare-metal stent implants. And their solution opens up a door to treating long-term stent patients and helping to boost their survival rates.
When studies of AbbVie's chloesterol drug Niaspan raised questions about its effectiveness, analysts suggested it would lose its blockbuster status. But in the face of falling sales, AbbVie's former parent Abbott Laboratories simply raised the price.
In the fiercely competitive global stent market, Abbott seems to view size as mattering most.
After four years, patients with Abbott's MitraClip cardiac device required additional operations, and the benefits of the device were no better than those of traditional mitral valve surgery, a follow-up look at participants in company's pivotal EVEREST II trial concludes.
Resentment appears to be growing among multinational medical device companies over India's decision in February to slash reimbursement for drug-eluting stents.
Becton Dickinson will ally with a University of Pennsylvania spinout to develop a new blood diagnostic test that gauges heart attack and stroke risk for individual patients, bringing it into an increasingly competitive market space.
Johnson & Johnson, Abbott, St. Jude Medical and Quest Diagnostics are already experiencing new declines in demand for non-emergency medical devices and diagnostic tests. And that reality will likely spread to their competitors, Reuters reports. Blame the gradual ramp-up of the Affordable Care Act, which is likely to broaden the trend through much of the med tech industry in the months ahead.
The agreement follows the start of a Phase I study of the compound, EPZ-5676, for which biotech giant Celgene has partnered with the startup for development outside the U.S.
Abbott is adding to the springtime list of diabetes-related device recalls, this time for a line of its blood glucose meters the company sells in the United States.